Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OV 4041

Next Previous
Search
Drug Profile

OV 4041

Alternative Names: OV-4041

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ovid Therapeutics
  • Class Antipsychotics; Anxiolytics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action K Cl-cotransporter agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Generalised anxiety disorder; Rett syndrome

Most Recent Events

  • 03 May 2025 OV 4041 is available for licensing as of 03 May 2025. https://ovidrx.com/
  • 31 Mar 2025 Ovid Therapeutics announces intention to submit IND application in second half of 2026
  • 31 Dec 2024 Preclinical trials in Anxiety disorders in USA (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top